Culver City-based ImmunityBio, Inc., a leading immunotherapy company, has announced that the U.S. Food and Drug ...
A new study published in AI in Precision Oncology examines the ability of large language models (LLMs) to rapidly extract ...
17h
Pharmaceutical Technology on MSNFDA approves BeiGene’s Tevimbra plus chemo for oesophageal cancerThe US Food and Drug Administration (FDA) has approved BeiGene’s Tevimbra (tislelizumab-jsgr) along with platinum-containing ...
Striking study results last year indicated a new type of medicine may improve on Merck’s immunotherapy, spurring a wave of ...
Tislelizumab plus chemotherapy received FDA approval as a frontline therapy for individuals with unresectable or metastatic ...
BeiGene's Tevimbra wins FDA approval for first-line metastatic ESCC treatment, showing significant survival benefits in PD-L1 ...
Esophageal squamous cell carcinoma accounts for approximately 90% of all esophageal cancer cases. Projections estimate that ...
The researchers found that factors favoring chemoimmunotherapy included higher socioeconomic status, being uninsured, a more ...
Checkpoint Therapeutics gains approval for cosibelimab but faces financial challenges and tough competition. Learn more about ...
David Zhen, MD, discussed the relevance of nivolumab in the upper gastrointestinal cancer population. In an interview with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results